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Flipping the Switch from Monomeric to Dimeric CV-N
Has Little Effect on Antiviral Activity
ture (Yang et al., 1999a; Barrientos et al., 2002). The
structure of the monomer in solution consists of two
domains, AM (residues 1–38/90–101) and BM (residues
Laura G. Barrientos,1,2,* Fa´tima Lasala,3
Rafael Delgado,3 Anthony Sanchez,2
and Angela M. Gronenborn1,*
1Laboratory of Chemical Physics 39–89), each containing a triple-stranded  sheet with
a  hairpin on top, that are connected by two helicalNational Institute of Diabetes
and Digestive and Kidney Diseases turns (Figure 1). Domain BM contains a helical linker in
the middle of the sequence (residues 50–56) whoseNational Institutes of Health
Bethesda, Maryland 20892 counterparts in domain AM are the N and C termini.
Each domain contains an oligosaccharide binding site,2 Special Pathogens Branch
DVRD, NCID exhibiting essentially similar affinities for different oligo-
mannosides (Shenoy et al., 2002). In the domain-Centers for Disease Control and Prevention
Atlanta, Georgia 30333 swapped dimer, two protein molecules exchange part
of their structure to form an intertwined dimer, exhibiting3 Laboratory of Molecular Microbiology
Hospital 12 de Octubre identical local structure to the monomer, except for the
hinge loop, which is helical in the monomer but essen-28041 Madrid
Spain tially extended and flexible in the dimer (Figure 1). Using
the domain notation of the monomer introduced above
and elsewhere (Barrientos and Gronenborn, 2002, 2004),
the domain-swapped dimer contains the following fourSummary
domains, all of which can be utilized for oligosaccharide
binding (Barrientos and Gronenborn, 2002): domains ADCyanovirin-N can exist in solution in monomeric and
domain-swapped dimeric forms, with HIV-antiviral ac- (residues 1–38 and 90–101) and AD (residues 1–38
and 90–101), and domains BD (residues 39–50 and 51–tivity being reported for both. Here we present results
for CV-N variants that form stable solution dimers: the 89) and BD (residues 39–50 and 51–89) (Figure 1).
The folding and thermodynamic stabilities of the mo-obligate dimer [Q50]CV-N and the preferential dimer
[S52P]CV-N. These variants exhibit comparable G nomeric and dimeric forms of the wild-type protein, as
well as that of the stabilized [P51G] variant were pre-values (10.6 0.5 and 9.4 0.5 kcal.mol1, respectively),
similar to that of stabilized, monomeric [P51G]CV-N viously investigated and it was demonstrated that the
domain-swapped dimer in dilute solution is metastable(9.8  0.5 kcal.mol1), but significantly higher than
wild-type CV-N (4.1  0.2 kcal.mol1). During folding/ and slowly converts to the monomer (Barrientos et al.,
2002). In contrast, the domain-swapped dimer is theunfolding, no stably folded monomer was observed
under any condition for the obligate dimer [Q50] sole structure observed by X-ray crystallography to date
(Yang et al., 1999a; Barrientos et al., 2002; Botos et al.,CV-N, whereas two monomeric, metastable species
were detected for [S52P]CV-N at low concentrations. 2002a, 2002b). Single amino acid changes in the hinge
region of CV-N, i.e., S52P (Han et al., 2002) and Q50This is in contrast to our previous results for [P51G]
CV-N and wild-type CV-N, for which the dimeric forms (Kelley et al., 2002) resulted in almost exclusively dimeric
protein. Since both monomeric and dimeric proteinswere found to be the metastable species. The dimeric
mutants exhibit comparable antiviral activity against were reported to exhibit antiviral activity, the question
arose whether the monomer or dimer is the more activeHIV and Ebola, similar to that of wild-type CV-N and
the stabilized [P51G]CV-N variant. species. The Q50 mutant was reported to have at least
3.5 times more activity than wild-type CV-N in an HIV
fusion assay (Kelley et al., 2002) while the S52P mutantIntroduction
exhibited slightly reduced activity in a cellular test for
HIV infection (Han et al., 2002). It is not clear, however,The cyanobacterial lectin Cyanovirin-N (CV-N) (Boyd et
al., 1997) exhibits virucidal activity against a variety of whether or not these differences are significant or solely
reflect variability between the assay systems.enveloped viruses (Barrientos and Gronenborn, 2004,
and references therein). This broad spectrum of activity In order to directly compare the activities of these
“improved” variants with those of wild-type CV-N, weis mediated via interactions between the protein and
the di- and tri-mannose moieties at the terminal arms carefully assessed the thermodynamic stabilities of the
proteins and tested them in HIV and Ebola assays. Ourof N-linked high mannose oligosaccharides (Man-8 and
Man-9) on viral surface glycoproteins (Shenoy et al., results demonstrate that no significant differences in
activity are observed despite notable differences in sta-2002; Barrientos and Gronenborn, 2004, and references
therein). bility and dimerization constants.
CV-N comprises 101 amino acids and exhibits a com-
pact monomeric bilobal structure with pseudosymmetry
Results and Discussion(Bewley et al., 1998) or a domain-swapped dimeric struc-
CV-N exists either as a monomer or as a domain-*Correspondence: gronenborn@nih.gov (A.M.G.); lbarrientos1@cdc.
gov (L.G.B.) swapped dimer and their relative proportion can be
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Figure 1. Solution Structure of the Monomer and Domain-Swapped Dimer Wild-Type CV-N
For the monomer, domains AM (residues 1–38/90–101) and BM (residues 39–89) are shown in blue and magenta, respectively. For the dimer,
domains AD (1–38/90–101) and AD (1–38/90–101) are shown in blue, and domains BD (39–50/51–89) and BD (39–50/51–89) are shown in
magenta. The loop residues 50–56 are colored yellow. Side chains are displayed for Q50, P51, and S52. Disulfide bonds are shown in orange.
The N and C termini of each monomeric unit in the monomer and domain-swapped dimer are labeled N and C and N and C. (Accession
codes: 2EZM.pdb [monomer] and 1L5E.pdb [dimer].)
modulated by protein concentration, temperature, or 38C. Analytical gel filtration chromatography confirmed
mutagenesis. In particular, residues in the hinge-loop that at least 90% of the protein was dimeric.
(Q50, P51, and S52) (Figure 1) play a critical role in that We also tested whether thermal unfolding of
regard (Barrientos et al., 2002; Han et al., 2002; Kelley et [Q50]CV-N and [S52P]CV-N at low micromolar concen-
al., 2002; Mori et al., 2002). In order to derive a thorough trations is reversible. Samples at 20 M and 5 M were
understanding of the basic properties of these interest- heat denatured (95C) and allowed to refold by cooling
ing molecules and guide our attempts to further develop to 4C. As assessed by CD spectroscopy of the resulting
CV-N as microbicidal agent, the thermodynamic stabili- sample at 20C, 80% of the original signal intensity
ties and factors influencing the monomer-dimer equilib- was recovered for [Q50]CV-N after complete unfolding.
rium for [S52P]CV-N and [Q50]CV-N, compared with This indicates that 20% of the sample irreversibly ag-
those of wild-type CV-N and [P51G]CV-N, were investi- gregated and precipitated upon heat treatment. A similar
gated. signal intensity loss was observed for [S52P]CV-N. In
addition, however, a further change in the spectra was
noted for this mutant. We therefore examined the 20 MDiscovery of a Metastable Monomer
samples of both mutants also by NMR and multiangleof [S52P]CV-N
light scattering. Data from both techniques corroboratedWe previously demonstrated for dimeric wild-type- and
the presence of only dimeric [Q50]CV-N after refolding[P51G]CV-N that incubation at 38C slowly converted
(Figure 2A), accompanied by moderate sample lossthe domain-swapped dimer to monomer (Barrientos et
(25%). Keeping this sample at 38C for a further periodal., 2002). Here we performed the analogous experi-
of three weeks did not reveal any other species. In thements for dimeric [Q50]CV-N and [S52P]CV-N. For
case of [S52P]CV-N, however, in addition to dimer, mo-three total protein concentrations, 20, 50, and 100 M,
nomeric protein was detected by light scattering (blackincubation at 38C was followed by NMR and we ob-
trace in Figure 2B). NMR analysis revealed that 2-foldedserved for the samples at 50 and 100 M that over
monomers were present in the sample, as evidencedtime, significant precipitation occurred. The only protein
by the presence of three cross peaks for the Trp49N1Hspecies that remained soluble and could be identified
resonance in the 1H-15N HSQC spectrum (Figure 3). Allby NMR were folded domain-swapped dimers. The rate
three cross-peaks reside in the folded region of theof precipitation was fastest for the 100M samples. For
spectrum (note that the Trp49 N1H cross-peak of un-both proteins at low concentration (20M), no precipita-
folded CV-N would be located at 10.1 ppm/140ppm).tion was apparent and the domain-swapped dimer re-
mained observable by NMR even after three weeks at From the ratio of peak intensities, it is possible to esti-
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Figure 2. Characterization of [Q50]CV-N and [S52P]CV-N CV-N Mutants by Size-Exclusion Chromatography in Conjunction with In-Line
Multiangle Light Scattering before and after Thermal Unfolding
(A) [Q50]CV-N and (B) [S52P]CV-N. Samples were unfolded at 95C and refolded by cooling to room temperature. Elution profiles were
monitored by refractive index (continuous lines) and the predicted molecular masses from light-scattering measurements (squares) are
displayed. The refractive index traces are shown for the protein before unfolding (red trace) and after refolding (blue). For [S52P]CV-N, a third
run was carried out after equilibrium was reached in the conversion reaction from monomer to dimer by heating at 38C (black UV-trace).
Data was recorded and analyzed using the ASTRA program.
mate a dimerization constant of 	50M. The presence M1 and monomer 2, M2) for the [S52P]CV-N was only
possible by NMR, and, although changes in the CDof monomeric [S52P]CV-N explains the changes de-
tected in the CD spectra described above. Surprisingly, spectra provided some hints, these changes could not
be translated into information about the appearance ofincubation of the sample containing the two monomeric
and the domain-swapped dimeric species at 38C re- a new species. Likewise, although gel filtration allowed
the identification and separation of monomer and dimer,vealed conversion of both monomers to dimer. This con-
version was complete after 2.5 hr (Figure 3) and no the presence of two different monomeric forms (M1 and
M2) could not be detected; only NMR made this possi-further changes were detected over a period of three
weeks (see blue trace, Figure 2B). ble. The spectra presented in Figure 3 were recorded
on a sample of 20 M total protein concentration, andAt this juncture, we wish to stress that all the above
NMR experiments were conducted on samples con- peak intensities at 0 time revealed relative proportions
of 26% dimer, 54% monomer 1, and 20% monomer 2.taining low micromolar protein concentrations. To ob-
tain high quality spectra on such low concentration sam- This demonstrates that protein of concentration as low
as 4 M can be detected and analyzed on a 600 MHzples has only recently become possible, using cryogenic
probes and their associated improved sensitivities. The spectrometer equipped with a cryoprobe.
The reversibility of GdnHCl unfolding was analyzed indiscovery of the two monomeric species (monomer 1,
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Figure 3. Selected Region of the 2D 1H-15N HSQC Spectra of Refolded [S52P]CV-N Illustrating the Conversion from Monomer to Dimer
The Trp49 N1H resonances were used as probes to follow the reaction at 38C. The left-hand side panel shows the spectrum of the protein
at 20C after thermal unfolding and refolding (see Experimental Procedures) prior to incubation at 38C. The right hand panel displays the
identical region after 2.5 hr incubation at 38C (both spectra were recorded at 20C). NMR measurements were carried out on samples
containing 20 M protein in 20 mM sodium phosphate buffer (pH 6.0). Dimeric [S52P]CV-N is labeled “D” and the monomeric forms are labeled
“M1” and “M2.”
the same fashion described above for thermal denatur- 4C). As for the monomeric species obtained after ther-
mal unfolding/refolding, the monomer was metastableation. [Q50]CV-N and [S52P]CV-N at two different pro-
tein concentrations (20 and 50 M) were unfolded in 8 M and converted quickly to dimer at room temperature
and above.GdnHCl and refolded by dialysis against 20 mM sodium
phosphate buffer (pH 6.0) at 4C. Samples were kept at
4C prior to data collection. At no point did we observe Stability of Domain-Swapped CV-N Dimers
The stability of monomeric and domain-swapped di-any protein precipitation for either [Q50]CV-N or
[S52P]CV-N at 20 or 50 M, indicating that a chaotropic meric wild-type CV-N and [P51G]CV-N was reported
previously (Barrientos et al., 2002). We showed that mo-agent solubilizes and stabilizes the denatured state of
a protein. GdnHCl unfolding curves, monitored by fluo- nomeric wild-type CV-N is slightly more stable than the
domain-swapped dimeric wild-type CV-N and reportedrescence spectroscopy, are shown in Figure 4, and the
insert in Figure 4B displays the light scattering results G values for folding of 4.2 kcal.mol1 for the monomer
(Barrientos et al., 2002). We also demonstrated that mu-for the 50 M sample of [Q50]CV-N before (red) and
after unfolding/refolding (blue) as monitored by refrac- tation of the single proline residue to a glycine resulted
in a significant increase in thermodynamic stability fortive index, respectively. No signal intensity loss was
noted, and only folded dimeric [Q50]CV-N was de- both monomer and domain-swapped dimer (G
 9.8
0.5 kcal.mol1 for the monomer; Barrientos et al., 2002).tected, demonstrating that chemical unfolding and re-
folding of this dimer is completely and quantitatively Our present work reports the stabilities of the obligate
dimer [Q50]CV-N and preferred dimer [S52P]CV-N inreversible. For the 50 M sample of [S52P]CV-N, the full
amount of refractive index was recovered, although a order to further our understanding of the delicate bal-
ance involved in the folding reaction of these structures.small amount of monomer (1%) was observed (Figure
Figure 4. Denaturation Curves and Refrac-
tive Index Traces
(A) GdnHCl denaturation curves for dimeric
[S52P]CV-N (circles) and [Q50]CV-N (trian-
gles). The unfolding transitions were moni-
tored by Trp fluorescence with excitation at
280 nm. Raw data were converted to the frac-
tion of folded molecules and plotted against
GdnHCl concentrations. The solid lines repre-
sent nonlinear least-squares fits of the data
to a two-state model. All measurements were
carried out at 20C on samples containing 50
M protein ([S52P]CV-N and [Q50]CV-N) in
20 mM sodium phosphate buffer (pH 6.0). Ex-
tracted thermodynamic parameters are sum-
marized in Table 1. Reversibility of protein
unfolding was verified by size-exclusion
chromatography in conjunction with in-line
multiangle light scattering. The refractive in-
dex-traces before unfolding in 8 M GdnHCl
(pH 6.0) and refolding for [Q50]CV-N (B) and
[S52P]CV-N (C) are shown in red and blue,
respectively.
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Table 1. Thermodynamic Parameters
T1/2 [GdnHCl]1/2 G m
Protein (C) (M) (kcal·mol1) (kcal·mol1·M1)
Q50 (D) 50.2  0.5 1.7  0.1 10.6  0.5 7.6  0.4
S52P (D) 53.5  0.5a 2.2  0.1 9.4  0.5 5.4  0.3
The GdnHCl unfolding was carried out on samples containing 50 M protein.
a Two transitions are resolved in the thermal unfolding curve of S52P; the midpoints are at 36.8C (dimer↔monomer transition) and 53.5C
(dimer unfolding).
Thermal melting curves (not shown) were monitored us- The Folding Landscape of CV-N
Elucidating factors important for protein stability anding CD spectroscopy at low protein concentration (20
M, to prevent protein precipitation as discussed above) identification of folding intermediates are of critical im-
portance for understanding the energy landscape ofand the resulting melting temperatures are listed in Ta-
ble 1. [Q50]CV-N melts cooperatively with a Tm of proteins. Here we show that the energy landscape of
CV-N is a highly dynamic entity and can be modulated by50.2C, considerably lower than the apparent Tm of mo-
nomeric wild-type CV-N101aa (61.3C) and [P51G]CV-N experimental conditions and mutagenesis. In particular,
protein concentration and temperature play crucial roles(71.2C). The thermal unfolding curve of [S52P]CV-N ex-
hibits two well resolved transitions, at 36.8 and 53.5C. in determining whether a metastable intermediate can
be trapped and structurally characterized. Likewise, mu-Since we know from the analysis presented in the pre-
vious section of this manuscript that monomeric tagenesis of pivotal residues (Q50, P51, and S52 in the
hinge loop, Figure 1) can have substantial and surprising[S52P]CV-N converts readily to domain-swapped dimer
at room temperature and above, we attribute the first effects. While the P51G mutation led to an overall stabili-
zation of monomer and domain-swapped dimer formstransition to the monomer-dimer conversion and the
second transition to the thermal melting of the domain- of the protein (Barrientos et al., 2002), the S52P mutation
shifted the proportion of monomer/dimer almost com-swapped dimer. Related results were previously ob-
tained for the metastable dimeric species of wild-type pletely toward the dimeric form (Han et al., 2002) and
deletion of Q50 yielded exclusively the domain-swappedCV-N and [P51G]CV-N. For these proteins, thermal un-
folding also showed two transitions, with the first transi- dimer (Kelley et al., 2002) (Figure 5). Therefore, shorten-
tion around 37C (in this case, the conversion proceeds ing the hinge loop by one amino acid (Q50 mutant) or
from domain-swapped dimer to monomer) and the sec- stiffening this link by introducing a second proline (S52P
ond transition at 61.3C for wild-type CV-N101aa and mutant) is entropically less favorable for folding into the
71.2C for [P51G]CV-N, reflecting thermal unfolding of compact monomeric form. For the [Q50]CV-N variant,
the monomer. this results in only unfolded monomer and folded dimer
Analysis of GdnHCl unfolding curves for the dimer being observed (Figure 5), whereas for [S52P]CV-N, de-
samples (50 M protein concentration) of [Q50]CV-N pending on conditions, monomer and dimer can be de-
and [S52P]CV-N was carried out assuming a two-state tected (Figure 5). In particular, the existence of two dif-
model with the equilibrium between unfolded monomer ferent monomeric species can be discerned, most likely
and folded dimer. Since for [Q50]CV-N we never ob- associated with cis-trans proline isomerization. Prolines
served a folded monomer irrespective of conditions, it are known to influence protein conformation and flexibil-
is justified to assume that only folded dimer is present ity and tandem prolines have been found to give rise to
through the folding transition. This is most likely also multiple conformations in peptides. For the present
the case for [S52P]CV-N, although a small amount of case, we speculate that the major monomeric species
folded monomer cannot be excluded. We therefore as- may contain both prolines in the trans conformation,
sumed the simple equilibrium of Dimerfolded↔2 Mono- while a cis proline for one of the two neighboring prolines
merunfolded. Analysis of the unfolding curves as specified may account for the minor monomeric form.
in Experimental Procedures yielded the following folding The most intriguing observation pertains to the switch
free energies: GQ50(D) 
 10.6  0.5 kcal.mol1 and between monomer and domain-swapped dimer as the
GS52P(D)
 9.4 0.5 kcal.mol1 (Table 1). The stabilities thermodynamically most stable state at 37C from the
of the two dimers are clearly greater than twice that of wild-type CV-N sequence to the S52P mutant. For both
the monomer wild-type CV-N 2  4.2 
 8.4 kcal.mol1 proteins, we were able to trap the metastable form by
(Barrientos et al., 2002), but similar to that of monomeric adjusting the protein concentration in the folding reac-
[P51G]CV-N (9.8 kcal.mol1). This implies that compared tion, using high and low concentrations for wild-type
to wild-type CV-N, the differences in free energy for the and [S52P]CV-N, respectively. This allowed us to clearly
dimeric mutants must reflect the differences in energies demonstrate that the single amino acid change S52P
of the hinge residues. Given the fact that our current switches the trapped, metastable quaternary state of
work yielded a dimerization constant of 	50 M for CV-N from dimer to monomer (Figure 5).
[S52P]CV-N at 20C, we wish to point out that our previ-
ous estimate ofGS52P
 4.2 0.4 kcal.mol1 (Barrientos
Biological Activity of Monomericet al., 2002) mainly reflects unfolding of the monomer,
versus Dimeric CV-Ngiven that at the protein concentration used at that time
Since CV-N can exist as a monomer or a dimer, the(10–20 M), the majority of the protein is monomeric
and not dimeric. question arose as to which of these two forms is the
Structure
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Figure 5. Schematic Representation of the
Folding Landscape and Free Energy Dia-
grams for CV-N
Refolding of three of the CV-N variants inves-
tigated (wild-type CV-N, [P51G]CV-N, and
[S52P]CV-N) revealed kinetically trapped in-
termediates, and the folding landscape con-
tains pronounced valleys and hills. Only
[Q50]CV-N exhibits a smooth landscape
and solely folded dimer and unfolded mono-
mer are present. For all other variants, un-
folded (Mu) and folded states (Mf, M1f, M2f,
and Df) are observed and their equilibria are
indicated by arrows (→) in the right-hand side
of the figure. Landscapes were drawn using
the program SigmaPlot.
more potent antiviral molecule. It was shown that mono- we found that binding of the domain-swapped dimers,
either the obligate one or the preferred one, was identi-meric, wild-type CV-N contains two carbohydrate bind-
ing sites for high mannose glycans (Shenoy et al., 2002) cal to that of the monomer. The small differences ob-
served for HIVgp120 and EboZ GP1 are due to the smallerand that the dimer can also bind these sugars (Bar-
rientos and Gronenborn, 2002; Botos et al., 2002a). We content of high-mannose oligosaccharides in the latter
(Barrientos et al., 2003). Therefore, our binding data didsubjected purified dimeric and monomeric wild-type
CV-N to cellular XXT-tetraxolium assays for anti-HIV ac- not indicate that the domain-swapped dimer species
has any higher biological activity than the monomerictivity under identical conditions (Barrientos et al., 2002)
and found identical activity for both species (Table 2). proteins. For conformation, we performed additional in-
fection assays and all CV-N proteins were carefully as-Similarly, [S52P]CV-N was tested, and a 7.7-fold de-
crease in activity compared to wild-type CV-N was found sessed and quantitated as described in Experimental
Procedures. We selected [P51G]CV-N as the monomeric(Han et al., 2002; Table 2). Since the cellular assays are
carried out at 37C and require a lengthy time (days), CV-N of our choice since it is more stable than wild-
type CV-N. In addition, [P51G]CV-N has performed con-any dimeric wild-type CV-N would convert to monomer
and monomeric [S52P]CV-N might be present under sistently and statistically better than wild-type CV-N in
a number of biological assays in our hands for a widethese assay conditions. Therefore, this question could
not be answered using wild-type CV-N (or the P51G range of viruses (including HIV [Mori et al., 2002; Table
2], influenza [O’Keefe et al., 2003; Table 2] and Ebolamutant) or [S52P]CV-N. Interestingly, testing dimeric
[Q50]CV-N and wild-type CV-N side by side with mono- [Table 2]) and cell lines. As dimeric CV-N of our choice,
we selected [Q50]CV-N since for no condition did wemeric wild-type CV-N in an HIV cell fusion assay, both
dimers were reported to be 3.5-fold more active than ever observe folded, monomeric protein. Two HIV infec-
tion assays were performed independently. The firstthe monomer (Kelley et al., 2002; Table 2). Here, we
tested the binding of [S52P]CV-N and [Q50]CV-N to assay makes use of the HIV-1 Ba-L virus and PBMC
cells and monitors the percentage of cells positive forHIV and Ebola Zaire (EboZ) env glycoproteins (gp120
and GP1, respectively), and compared this binding to p24 by FACS. Identical antiviral activity (EC50 of 6.25 nM)
was found for both [P51G]CV-N and [Q50]CV-N (Tablethat of monomeric [P51G]CV-N (Table 3). In all cases,
Folding and Antiviral Activity of Cyanovirin-N
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Table 2. Comparison of Antiviral Activity of Monomeric and Dimeric CV-N
CV-Nh
Virus Strain Target Cells Virus Assay wtCV-N (M) wtCV-N (D) P51G (M) Q50 (D) S52P (D)
HIV-1 Ba-L PBMC IC p24a – – 6.25 6.25 1.5
HIV-1 Ba-L TZM-bl Luciferasea 16  4 – 4.0  1.5 6.7  2.7 0.75  0.15
EboZpseudo HeLa Luciferasea,g 50  10g – 40.5  21.5 203.5  67.5 71  23
HIV-1 WeJo PBMC XXT-tetraxoliumb 43.6  17.0 – 3.3  1.3 – –
HIV-1 Ba-L monocytes XXT-tetraxoliumb 18.7  10.7 – 9.8 – –
HIV-1 RF CEM-SS XXT-tetraxoliumb 0.49  0.35 – 0.1  0.05 – –
HIV-1 RF CEM-SS XXT-tetraxoliumc 0.19 – – – 1.46
HIV-1Vaccinia HeLa cell fusiond 32 9 – 9 –
HIV-1 RF CEM-SS XXT-tetraxoliume 1 1 – – –
A/Sydney/05/97 (H3N2) MDCK CPEf 0.026  0.0023 – 0.015  0.014 – –
All data represent the 50% effective concentration [EC50 (nM)]. When available, the SD for the mean value of EC50 are provided ().
a Assays were performed according to Experimental Procedures.
b Values from Mori et al. (2002).
c Values from Han et al. (2002).
d Values from Kelley et al. (2002).
e Values from Barrientos et al. (2002).
f One representative anti-influenza activity from O’Keefe et al. (2003).
g Values from Barrientos et al. (2004).
h The aggregation state of the molecules before viral assays is specified by M (monomeric) and D (dimeric). Based on studies performed here
and elsewhere (Barrientos et al., 2002), it is likely that wtCV-N(D) and S52P(D) actually coexists with the monomeric species at the low protein
concentration used in the assays.
2). The second assay uses the HIV-1 Ba-L virus on the cellular hosts used in the assays, given that the activity
is carbohydrate-dependent and the sugar content onsensitive indicator TZM-bl cell and luciferase activity is
measured 48 hr after infection (Wei et al., 2002). Both the virus env may be influenced by the host’s machinery.
Taking all the data in to consideration, we believe thatproteins are essentially equally active in this assay and
exhibit EC50 concentrations of 4.0  1.5 nM and 6.7  all the molecules studied here exhibit essentially similar
antiviral activity. For practical purposes, however, the2.7 nM for [P51G]CV-N and [Q50]CV-N, respectively.
The in vitro potency of [P51G]CV-N and [Q50]CV-N in [P51G]CV-N mutant offers the benefit of very high ther-
modynamic stability and ease of preparation and there-inhibiting EboZ GP-pseudotyped virus from mediating
transduction in HeLa cells revealed an EC50 of 40.5  fore would be the molecule of choice in any in vivo tests.
21.5 nM and 203.5 67.5 nM, respectively. In this assay,
monomeric [P51G]CV-N appeared slightly more effec- Conclusion
tive than the domain-swapped dimeric protein, although Information about folding, stability, and antiviral proper-
these values are essentially very similar, given the exper- ties of the potent HIV-inactivating protein CV-N in the
imental errors in these measurements. We also included two alternative quaternary structures is crucial for de-
activity data for [S52P]CV-N in Table 2, and, as can signing improved homologs. Here we demonstrated that
be appreciated, similar activity to [P51G]CV-N and a single amino acid change, S52P, can result in switch-
[Q50]CV-N is seen, although it is not clear how much ing the thermodynamically most stable state from a mo-
monomer and swapped dimer would be present under nomer to a domain-swapped dimer. In addition, the
assay conditions. monomeric state comprises two distinct conformers,
Given the above results, is it possible to state with caused by the presence of two neighboring prolines.
confidence whether the dimeric state is more active than Using pure monomeric and dimeric CV-N variants al-
the monomer for a given CV-N variant? The answer is lowed us to answer the question whether the monomer
not simple and requires a comprehensive evaluation of or domain-swapped dimer is the active form of CV-N.
all the factors that may influence the reported activity Essentially similar activities against HIV and Ebola for
values. Some of the factors are intimately connected to both forms were observed.
the folding and stability of the CV-N proteins, i.e., the
proportion of monomer and dimer that may be present
Experimental Procedures
under assay conditions. Others are connected to the
Cloning and Expression
The synthetic gene of [P51G]CV-N coding for amino acids
Table 3. Binding of Monomeric and Dimeric CV-N to HIV-1 [L1…G51…E101] was inserted into pET26b() (Novagen; Madison,
gp120 and EboZ GP1 WI) as described previously (Mori et al., 1998). The two mutants,
[Q50]CV-N and [S52P]CV-N were constructed in the P51G back-P51G (M) Q50 (D) S52P (D)
ground by site-directed mutagenesis using the QuikChange Site-
HIV-1 gp120 4 4 5 Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with the follow-
EboZ GP1 10 10 10 ing forward/reverse primer pairs (Invitrogen; Carlsbad, CA) [5-CGT
TGACGGTTCCCTGAAATGGCCGTCCAACTTCATCGAAACCTGAll data represent the midpoints [nM] extracted from the Elisa satu-
CCG-3/5-CGGCAGGTTTCGATGAAGTTGGACGGCCATTTCAGGGration curve.
AACCGTCAACG-3] and [5-CGTTGACGGTTCCCTGAAATGGCAG
Structure
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CCGCCGAACTTCATCGAAACCTGCCG-3/5-CGGCAGGTTTCGAT
G 
 RTlnK 
 RTln2Pt f
2
U
1  fU
GAAGTTCGGCGGCTGCCATTTCAGGGAACCGTCAACG-3]. The
identity of each construct was confirmed by nucleotide sequencing.
with R the gas constant (1.987 cal·deg1·mol1), T the absolute tem-All proteins were expressed in Escherichia coli BL-21(DE3) and uni-
perature (K), fu the apparent fraction of unfolded molecules, and Ptformly 15N-labeled using common procedures.
the total protein concentration.
Purification and Folding
All proteins were isolated from the periplasmic fraction of E.coli (the Preparation of Monomeric [S52P]CV-N and Conversion
expression vector used carries a pelB signal) by twice heating/ of Monomer to Dimer
cooling the cells suspended in PBS buffer (pH 7.4). In this fashion A solution containing 5–20M [S52P] CV-N was unfolded by dialysis
70, 25, and 25 mg/L of cell culture of properly folded, soluble protein overnight against 6 M GdnHCl containing sodium phosphate buffer
was isolated for the P51G, Q50, and S52P mutants, respectively. (20 mM [pH 6.0]) at 4C. Subsequently, the protein was refolded by
Losses caused by precipitation occurred for Q50 and S52P but extensive dialysis against the same buffer without GdnHCl at 4C.
none were detected for P51G. Reasonable protein purity (80%–90%) No precipitate was observed. Refolding at low protein concentration
can be obtained by a single gel-filtration step. Improved purity was yielded a mixture of monomer and dimer, in a concentration-depen-
achieved by first denaturating the protein in 6 M guanidinium hydro- dent manner. Maintaining the sample at low temperature, 300 l of
chloride (GdnHCl) in 20 mM sodium phosphate buffer (pH 6.0), with the protein solution was transferred to a Shigemi NMR tube and
subsequent gel filtration on Superdex-75 (HiLoad 2.6 cm  60 cm, immediately subjected to NMR analysis. NMR data were collected
Amersham Pharmacia Biotech, NJ) in the same buffer. Peak frac- at 20C. Conversion from monomer to dimer was carried out by
tions were pooled, and the protein was refolded by dialysis against placing the remaining sample into a thermostated water bath at
buffer without GdnHCl. The final purification step for the refolded 38C. Aliquots were subjected to NMR analysis (at 20C) at given
protein involved chromatography on Superdex-75 in 20 mM sodium intervals and also analyzed by multiangle light scattering.
phosphate buffer (pH 6.0). In this manner [P51G]CV-N was isolated
as a pure monomer, while [Q50]CV-N and [S52P]CV-N were iso- Size Exclusion Chromatography and Multiangle
lated as dimers. The identity and purity of the proteins were verified Light Scattering
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis Light scattering data were obtained using an analytical superdex-
(SDS-PAGE) and mass spectrometry, and conformational properties 75 column (1.0  30 cm; Amersham Biosciences, Piscataway, NJ)
were assessed by NMR and multiangle light scattering. All proteins with in-line multiangle light scattering (DAWN EOS, Wyatt Technol-
were stored at 4C. ogy, Inc., Santa Barbara, CA) and refractive index (OPTILAB DSP,
Wyatt Technology, Inc., Santa Barbara, CA) and UV (Waters, Inc.)
Protein Concentration detectors. Twenty to one hundred micrograms of proteins in 75–150
The quantity of CV-N in each sample was determined by refractive l of 20 mM sodium phosphate buffer (pH 6.0) containing 0.02%
index detection (OPTILAB DSP, Wyatt Technology, Inc., Santa Bar- sodium azide were applied to the preequilibrated S75 column at a
bara, CA) using a [P51G]CV-N stock solution as a reference that flow rate of 0.5 ml/min at room temperature and eluted with the
was previously quantitated by amino acid analysis using a Hitachi same buffer.
Model #L8800 amino acid analyzer (analysis courtesy of Ray Sowder
of SAIC-Frederick). The quantity of all CV-N samples was further
Nuclear Magnetic Resonance
confirmed by UV absorbance (280 nm) using a molar extinction
NMR spectra were recorded for 15N-labeled CV-N in 20 mM sodium
coefficient of 10220/M/cm and by densitometry of SDS gels after
phosphate buffer (pH 6.0), containing 90% H2O/10% D2O at 20C orcalibration. It was verified by NMR and multiangle light scattering
38C using an UltraShield Bruker DRX600 spectrometer equipped
that the stock solutions of [P51G]CV-N, [Q50]CV-N, and [S52P]CV-N
with a cryo-probe. Spectra were processed and analyzed with
contained monomer, dimer, and dimer, respectively.
NMRPipe (Delaglio et al., 1995).
Thermal and Chemical Denaturation
Preparation of GP1 from Ebola Virion ParticlesThermal melting was monitored by CD spectrometry, measuring the
GP1 was isolated from inactivated EboZ virion particles (1976 Ma-far-UV molar ellipticity at 200 nm on a J-720 spectropolarimeter
yinga strain) from the tissue culture fluid of infected Vero E6 cells(JASCO, Easton, MD) equipped with a thermostatic cell holder
as detailed in Sanchez et al. (1998) and Barrientos et al. (2003). Virion(Thermo NESLAB) using 0.1cm cells. Data were collected as a func-
proteins were separated by SDS-PAGE and GP1 was subsequentlytion of temperature with a scan rate of 0.5C/min over the tempera-
electroeluted from Coomassie blue-stained gel. Purified protein wasture range of 5C–85C in 10 mM sodium phosphate buffer (pH 6.0).
quantitated by SDS-PAGE gel stained with silver.Unfolding curves were measured for different protein concentration
(100, 50, 20, and 5 M) and monitored by CD and NMR.
Equilibrium (un)folding induced by guanidine hydrochloride Biological Assays
Binding of CV-N to glycosylated soluble HIV-1 gp120 (Intracel Corp.)(GdnHCl) was monitored by steady-state tryptophan fluorescence.
Individual protein samples were prepared in 20 mM sodium phos- and EboZ GP1 was assessed by ELISA as detailed in Barrientos et al.,
2003. For the infection experiments, HIV and Ebola-GP pseudotypedphate buffer (pH 6.0), containing the desired amount of GdnHCl
(Ultra pure, US Biochemicals, Cleveland, OH). The GdnHCl concen- lentiviruses were handled under biosafety level 3 procedures ac-
cording to standard recommendations.tration of the stock solution was determined by refractive index
measurements using a refractometer (Bausch & Lomb, Rochester, EboZ GP pseudotyped lentivirus particles were used to study
the in vitro potency of CV-N to inhibit EboZ GP-mediated geneNY). Experiments were carried out for protein concentrations of
50 M for [S52P]CV-N and [Q50]CV-N. Samples were incubated transduction into HeLa cells (Barrientos et al., 2004). The lentiviral
vector pNL4-3.Luc.RE was obtained from Dr. Nathaniel Landauovernight at 20C to ensure that equilibrium was reached prior to
the measurement. Reversibility of unfolding was also assessed (He et al., 1995) through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, and was used forby NMR.
Fluorescence spectra were recorded on a Model LS-50B spec- production of Ebola GP pseudotypes using a transient transfection
protocol with 293T cells as previously described (Yang et al., 1999a).trofluorometer (Perkin-Elmer, Wellesley, MA) equipped with a tem-
perature-controlled water bath (Thermo NESLAB, Portsmouth, NH). Supernatant fluids were obtained 48 hr after transfection, filtered
(0.45 m pore) and stored frozen (80C). Supernatant fluids con-Measurements were performed with a scan speed of 120 nm/min
and data intervals of 0.5 nm. An excitation wavelength of 280 nm taining Ebola GP-pseudotyped lentiviruses were treated with differ-
ent concentrations of CV-N and its variants for 20 min at RT andwas used, and the intrinsic fluorescence (I330/I360) was recorded. The
equilibrium constant, K, and the free energy of folding, G, for the added onto HeLa cell monolayers in 24-well plates at an MOI of 0.1
using DMEM-10% FBS. Infectivity was measured 48 hr after infec-dimers were calculated using the following equation (Kuhlman et
al., 2001): tion by luciferase assay using reagents from Promega (Madison,
Folding and Antiviral Activity of Cyanovirin-N
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Wisconsin) in a Berthold Sirius luminometer (Berthold, Munich, of the complexes of a potent anti-HIV protein cyanovirin-N and high
mannose oligosaccharides. J. Biol. Chem. 277, 34336–34342.Germany).
The anti-HIV activity was characterized using two independent Botos, I., Mori, T., Cartner, L.K., Boyd, M.R., and Wlodawer, A.
methods: (1) Supernatants containing the HIV Ba-L strain grown in (2002b). Domain-swapped structure of a mutant of cyanovirin-N.
PBMC were treated with CV-N as described above and used to Biochem. Biophys. Res. Commun. 294, 184–190.
infect TZM-bl cells obtained from Dr. John C. Cappes, Dr. Xiaoyun Boyd, M.R., Gustafson, K.R., McMahon, J.B., Shoemaker, R.H.,
Wu, and Tranzyme, Inc. through the NIH AIDS Research and Refer- O’Keefe, B.R., Mori, T., Gulakowski, R.J., Wu, L., Rivera, M.I., Lauren-
ence Reagent Program (Wei et al., 2002). Infection and measurement cot, C.M., et al. (1997). Discovery of cyanovirin-N, a novel human
of luciferase activity were performed as described for Ebola GP- immunodeficiency virus-inactivating protein that binds viral surface
pseudotypes; (2) the percentage of cells p24 positive by FACS was envelope glycoprotein gp120: potential applications to microbicide
determined (antiviral activity kindly provided by Laurel Lagenaur development. Antimicrob. Agents Chemother. 41, 1521–1530.
[NIAID] and Qiang Xu [OSEL, Inc.]). In brief, samples were diluted
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax,in DMEM in a V bottom dish. HIV Ba-L was added, equivalent MOI

A. (1995). NMRPipe: a multidimensional spectral processing system0.1. Samples were incubated with virus 1 hr at 37C and added to
based on UNIX pipes. J. Biomol. NMR 6, 277–293.10e6 IL-2-stimulated PBMC. Indinavir was added to prevent cell-
Han, Z., Xiong, C., Mori, T., and Boyd, M.R. (2002). Discovery ofto-cell spread. The medium was changed at 24 hr and samples were
a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-fixed and stained for p24 via FACS.
displayed CV-N mutant library. Biochem. Biophys. Res. Commun.
292, 1036–1043.Acknowledgments
He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D.O., and Landau,
N.R. (1995). Human immunodeficiency virus type 1 viral protein RWe thank Pierre Rollin (NCID) and Gerhard Hummer (NIDDK) for
(Vpr) arrests cells in the G2 phase of the cell cycle by inhibitinguseful discussions and Andy Myer (Wyatt Technology) for technical
p34cdc2 activity. J. Virol. 69, 6705–6711.support regarding multiangle light scattering. We acknowledge the
help of Ray Sowder (SAIC-Frederick) in kindly quantitating [P51G]CV-N Kelley, B.S., Chang, L.C., and Bewley, C.A. (2002). Engineering an
by amino acid analysis and thank Laurel Lagenaur (NIAID) and Qiang obligate domain-swapped dimer of cyanovirin-N with enhanced
Xu (OSEL, Inc.) for providing independent anti-HIV activity for our anti-HIV activity. J. Am. Chem. Soc. 124, 3210–3211.
CV-N variants using an IC p24 assay (Table 2). This research was Kuhlman, B., O’Neill, J.W., Kim, D.E., Zhang, K.Y.J., and Baker, D.
supported by the Intramural AIDS Targeted Antiviral Program of the (2001). Conversion of monomeric protein L to an obligate dimer
Office of the Director of the National Institutes of Health (to A.M.G.) by computational protein design. Proc. Natl. Acad. Sci. USA 98,
and by G03173 and PI030300 from FIS and 08.2/0001/2003 from 10687–10691.
Comunidad de Madrid (to R.D.). L.G.B. was supported by the Re-
Mori, T., Gustafson, K.R., Pannell, L.K., Shoemaker, R.H., Wu, L.,search Participation Program at the Centers for Disease Control
McMahon, J.B., and Boyd, M.R. (1998). Recombinant production ofand Prevention, National Center for Infectious Diseases, Division of
cyanovirin-N, a potent human immunodeficiency virus-inactivatingViral and Rickettsial Diseases administered by the Oak Ridge Insti-
protein derived from a cultured cyanobacterium. Protein Expr. Purif.tute for Science and Education through an interagency agreement
12, 151–158.between the U.S. Department of Energy and CDC.
Mori, T., Barrientos, L.G., Han, Z., Gronenborn, A.M., Turpin, J.A.,
and Boyd, M.R. (2002). Functional homologs of cyanovirin-N amena-Received: May 28, 2004
ble to mass production in prokaryotic and eukaryotic hosts. ProteinRevised: July 19, 2004
Expr. Purif. 26, 42–49.Accepted: July 21, 2004
O’Keefe, B.R., Smee, D.F., Turpin, J.A., Turpin, J.A., Saucedo, C.J.,Published: October 5, 2004
Gustafson, K.R., Mori, T., Blakeslee, D., Buckheit, R., and Boyd, M.R.
(2003). Potent anti-influenza activity of cyanovirin-N and interactionsReferences
with viral hemagglutinin. Antimicrob. Agents Chemother. 47, 2518–
2525.
Barrientos, L.G., and Gronenborn, A.M. (2002). The domain-
Sanchez, A., Yang, Z.Y., Xu, L., Nabel, G.J., Crews, T., and Peters,swapped dimer of cyanovirin-N contains two sets of oligosaccharide
C.J. (1998). Biochemical analysis of the secreted and virion glyco-binding sites in solution. Biochem. Biophys. Res. Commun. 298,
proteins of Ebola virus. J. Virol. 72, 6442–6447.598–602.
Shenoy, S.R., Barrientos, L.G., Ratner, D.M., O’Keefe, B.R., See-Barrientos, L.G., and Gronenborn, AM. (2004). The highly-specific
berger, P.H., Gronenborn, A.M., and Boyd, M.R. (2002). Multisitecarbohydrate binding protein Cyanovirin-N: structure, anti-HIV/
and multivalent binding between Cyanovirin-N and branched oligo-Ebola activity and possibilities for therapy. Mini Rev. Med. Chem.,
mannosides: calorimetric and NMR characterization. Chem. Biol. 9,in press.
1109–1118.
Barrientos, L.G., Louis, J.M., Botos, I., Mori, T., Han, Z., O’Keefe,
Yang, F., Bewley, C.A., Louis, J.M., Gustafson, K.R., Boyd, M.R.,B.R., Boyd, M.R., Wlodawer, A., and Gronenborn, A.M. (2002). The
Gronenborn, A.M., Clore, G.M., and Wlodawer, A. (1999a). Crystaldomain-swapped dimer of cyanovirin-N is in a metastable folded
structure of cyanovirin-N, a potent HIV-inactivating protein, showsstate: reconciliation of X-ray and NMR structures. Structure 10,
unexpected domain swapping. J. Mol. Biol. 288, 403–412.673–686.
Yang, S., Delgado, R., King, S.R., Woffendin, C., Barker, C.S., Yang,Barrientos, L.G., O’Keefe, B.R., Bray, M., Sanchez, A., Gronenborn,
Z.Y., Zu, L., Nolan, G.P., and Nabel, G.J. (1999b). Generation ofA.M., and Boyd, M.R. (2003). Cyanovirin-N binds to the viral surface
retroviral vector for clinical studies using transient transfection.glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral
Hum. Gene Ther. 10, 123–132.Res. 58, 47–56.
Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M.,Barrientos, L.G., Lasala, F., Otero, J.R., Sanchez, A., and Delgado,
Saag, M.S., Wu, X., Shaw, G.M., and Kaapes, J.C. (2002). EmergenceR. (2004). In vitro evaluation of Cyanovirin-N antiviral activity, by use
of resistant human immunodeficiency virus type 1 in patients receiv-of Lentiviral vectors pseudotyped with filovirus envelope glycopro-
ing fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemo-teins. J. Infect. Dis. 189, 1440–1443.
ther. 46, 1896–1905.
Bewley, C.A., Gustafson, K.R., Boyd, M.R., Covell, D.G., Bax, A.,
Clore, G.M., and Gronenborn, A.M. (1998). Solution structure of cya-
novirin-N, a potent HIV-inactivating protein. Nat. Struct. Biol. 5,
571–578.
Botos, I., O’Keefe, B.R., Shenoy, S.R., Cartner, L.K., Ratner, D.M.,
Seeberger, P.H., Boyd, M.R., and Wlodawer, A. (2002a). Structures
